Post-Finasteride syndrome ( PFS ) is a constellation of serious adverse side effects manifested in clinical symptoms that develop and persist in patients during and/or after discontinuing Finasteride treatment in men with pattern hair loss ( androgenetic alopecia ) or benign prostatic hyperplasia.
These serious adverse side effects include persistent or irreversible sexual, neurological, physical and mental side effects.
To date, there are no evidence-based effective treatments for post-Finasteride syndrome. Although increasing number of men report persistent side effects, the medical community has yet to recognize this syndrome nor are there any specific measures to address this serious and debilitating symptoms.
Researchers have evaluated the scientific and clinical evidence in the contemporary medical literature to address the very fundamental question: Is post-Finasteride syndrome a real clinical condition caused by Finasteride use or are the reported symptoms only incidentally associated with but not caused by Finasteride use ?
One key indisputable clinical evidence noted in all reported studies with Finasteride and Dutasteride was that use of these drugs is associated with development of sexual dysfunction, which may persist in a subset of men, irrespective of age, drug dose or duration of study.
Also, increased depression, anxiety and suicidal ideation in a subset of men treated with these drugs were commonly reported in a number of studies.
It is important to note that many clinical studies suffer from incomplete or inadequate assessment of adverse events and often limited or inaccurate data reporting regarding harm.
Based on the existing body of evidence in the contemporary clinical literature, Finasteride and Dutasteride can induce a constellation of persistent sexual, neurological and physical adverse side effects, in a subset of men.
These constellations of symptoms constitute the basis for post-Finasteride syndrome in individuals predisposed to epigenetic susceptibility.
Delineating the pathophysiological mechanisms underlying post-Finasteride syndrome will be of paramount importance to the understanding of this syndrome and to development of potential novel therapeutic modalities. ( Xagena )
Traish AM, Fertil Steril 2020; 113: 21-50